A groundbreaking discovery has emerged in the field of Alzheimer's research, leaving experts and patients alike with a sense of hope and curiosity. The potential for long-term benefits from a limited treatment period is a game-changer.
Dr. Jennifer Zimmer, from Eli Lilly, presented new data at the Clinical Trials on Alzheimer's Disease (CTAD) annual meeting, revealing that early-stage Alzheimer's patients who underwent donanemab (Kisunla) therapy for just 12 months experienced cognitive and functional improvements that lasted for an additional two years. But here's where it gets controversial: these benefits persisted even after the treatment ended.
The study focused on a subgroup of 325 participants who completed their treatment within the first year of the placebo-controlled period. These participants received blinded placebo infusions for the next two years. The results were remarkable: compared to an untreated external cohort, the subgroup showed a significant reduction in cognitive and functional decline, with scores improving by 0.6 points at one year and 1.1 points at two years, based on the Clinical Dementia Rating Sum of Boxes (CDR-SB) scale.
At three years, the CDR-SB difference was an impressive 1.3 points, indicating that the benefits of donanemab treatment continued even after patients stopped taking the medication. This finding challenges the conventional belief that Alzheimer's treatments must be ongoing to maintain their effectiveness.
The CDR-SB scale measures both cognitive and functional aspects, with higher scores indicating greater impairment. The untreated controls were sourced from the Alzheimer's Disease Neuroimaging Initiative (ADNI), carefully matched to key characteristics of the study participants.
Donanemab, a monoclonal antibody targeting specific forms of amyloid-beta plaques, was approved by the FDA in 2024 based on the randomized phase III TRAILBLAZER-ALZ 2 trial. This trial demonstrated that donanemab slowed clinical progression over 76 weeks. However, one potential concern is the risk of amyloid-related imaging abnormalities (ARIA), which can include ARIA with edema or effusions (ARIA-E) and ARIA with microhemorrhages or hemosiderin deposits (ARIA-H). The donanemab label carries a boxed warning about the potential seriousness of these side effects.
In the TRAILBLAZER-ALZ 2 trial, 860 participants were randomized to receive donanemab during the placebo-controlled period. The baseline characteristics of this group included a mean Mini-Mental State Examination (MMSE) score of 22.4 and a mean amyloid PET level of 103.5 centiloids, with 69.8% carrying at least one APOE4 allele. The subgroup of 325 participants who completed treatment within the first year had slightly better baseline scores, with a mean MMSE of 23.9 and a mean amyloid PET level of 90.8 centiloids, and 61.2% carrying the APOE4 allele.
The mean amyloid levels for participants who completed donanemab treatment by one year remained below 24.1 centiloids at three years. Dr. Zimmer explained that these data, combined with findings from other donanemab studies, suggest an estimated re-accumulation rate of 2.4 centiloids per year, similar to the natural accumulation rate in Alzheimer's disease.
Among participants who completed treatment within the first year, the frequencies of ARIA, ARIA-E, and ARIA-H after switching to placebo were 20.3%, 2.0%, and 18.3%, respectively. These frequencies were similar to those observed in participants randomized to placebo during the placebo-controlled period.
More detailed data on this subgroup and other participants in the long-term extension study of TRAILBLAZER-ALZ 2 were recently published in the Journal of Prevention of Alzheimer's Disease. It's important to note that all statistical analyses were exploratory and not controlled for multiplicity, and the long-term extension period lacked a true placebo comparator, potentially introducing survivor bias over time.
This study raises intriguing questions: Could a limited treatment period be sufficient to provide long-term benefits for Alzheimer's patients? What are the implications for treatment accessibility and cost? And this is the part most people miss: the potential for a paradigm shift in how we approach Alzheimer's treatment. With these findings, we might be witnessing a new era in Alzheimer's care. What are your thoughts on this groundbreaking research? Feel free to share your insights and opinions in the comments below!
